Time
Days to earnings13
Next print2026-10-29
WindowBMO
Fiscal2026-09-30
NASDAQ · HEALTHCARE · BIOTECHNOLOGY
ALNY
Alnylam Pharmaceuticals Inc primary
227.02
Full stocks workspace →-5.66-2.4%
Street
Consensus EPS2.311
Consensus revenue1.4B
EPS high / low3.446 / 1.94 · 65.2% · n=14
Rev / avg2 / — · 2.315 / 2.315
Options
IV front44.4%
Implied move9.6%
Put/call full0.65
Put/call front0.60
Short interest
Short shares7.7M / 7.2M · +7.19%
Days to cover6.45
Avg vol · float1.2M · 133.2M
Short % float5.79%
| Date | DTE | Next | Close | Cons. EPS | IV front % | Implied | Ret 5d | Ret 10d | Ret 20d | Ret 30d | EPS high / low | Dispersion | Analysts | P/C | Peers rpt | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-12 | 13 | 2026-10-29 | 227.02 | 2.311 | 44.4% | 9.6% | +3.2% | -11.1% | -9.2% | -4.3% | 3.446 / 1.94 | 65.2% | 14 | 0.65 | 0 | |
| 2026-10-09 | 14 | 2026-10-29 | 232.68 | 2.311 | 50.3% | 11.8% | +5.9% | -9.1% | -6.4% | -1.6% | 3.446 / 1.94 | 65.2% | 14 | 0.65 | 0 | |
| 2026-10-08 | 15 | 2026-10-29 | 224.53 | 2.311 | 45.9% | 11.0% | -2.9% | -10.0% | -9.3% | -6.1% | 3.446 / 1.94 | 65.2% | 14 | 0.65 | 0 | |
| 2026-10-07 | 16 | 2026-10-29 | 224.41 | 2.311 | 44.9% | 11.0% | -9.1% | -9.0% | -13.0% | -6.5% | 3.446 / 1.94 | 65.2% | 14 | 0.66 | 0 | |
| 2026-10-06 | 17 | 2026-10-29 | 223.94 | 2.311 | 48.3% | 12.1% | -11.9% | -11.0% | -13.9% | -5.1% | 3.446 / 1.94 | 65.2% | 14 | 0.65 | 0 | |
| 2026-10-05 | 18 | 2026-10-29 | 219.89 | 2.311 | 41.5% | 10.6% | -13.9% | -10.0% | -17.4% | -6.9% | 3.446 / 1.94 | 65.2% | 14 | 0.64 | 0 | |
| 2026-10-02 | 19 | 2026-10-29 | 219.72 | 2.315 | 47.3% | 12.9% | -14.2% | -8.3% | -16.9% | -4.2% | 3.446 / 1.94 | 65.0% | 14 | 0.64 | 0 | |
| 2026-10-01 | 20 | 2026-10-29 | 231.18 | 2.315 | 50.3% | 13.9% | -7.4% | -5.8% | -13.5% | -4.7% | 3.446 / 1.94 | 65.0% | 14 | 0.63 | 0 | |
| 2026-09-30 | 21 | 2026-10-29 | 246.74 | 2.315 | 43.9% | 12.4% | +0.1% | +3.1% | +0.3% | +7.9% | 3.446 / 1.94 | 65.0% | 14 | 0.63 | 0 | |
| 2026-09-29 | 22 | 2026-10-29 | 254.07 | 2.315 | 45.4% | 13.0% | +1.0% | +6.6% | +5.6% | +13.1% | 3.446 / 1.94 | 65.0% | 14 | 0.63 | 0 |
Linked names and their last print
| Peer | Name | Score | Last qtr | Last surprise | Reaction | 1-day close | DTE (full) |
|---|---|---|---|---|---|---|---|
| VRTX primary | Vertex Pharmaceuticals Inc | 0.26 | 2026Q2 · 2026-08-03 | +1.2% | +0.1% | 478.71 | 15 · 2026-10-12 |
| REGN primary | Regeneron Pharmaceuticals Inc | 0.13 | 2026Q2 · 2026-07-30 | +56.6% | +0.9% | 738.34 | 14 · 2026-10-12 |
| INSM primary | Insmed Inc | 0.12 | 2026Q2 · 2026-08-06 | +24.6% | +29.5% | 132.55 | 13 · 2026-10-12 |
| Fiscal qtr | Report date | Window | Actual EPS | Surprise % | Beat | Reaction | 1-day result | Vol ×10d | Post 10d | Review |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q2 | 2026-07-30 | BMO | 1.21 | -16.0% | Miss | -21.5% | -8.7% | 7.74× | +10.5% | Review |
| 2026Q1 | 2026-04-30 | BMO | 1.99 | +35.4% | Beat | +2.1% | +0.7% | 1.98× | -5.2% | Review |
| 2025Q4 | 2026-02-12 | BMO | 1.25 | -16.7% | Miss | -2.4% | -1.9% | 1.60× | +7.9% | Review |
| 2025Q3 | 2025-10-30 | BMO | 2.90 | +65.7% | Beat | -6.6% | -0.1% | 2.42× | +1.0% | Review |
| 2025Q2 | 2025-07-31 | BMO | 0.32 | +113.3% | Beat | +3.0% | +12.1% | 3.51× | +12.9% | Review |
| 2025Q1 | 2025-05-01 | BMO | -0.01 | +97.3% | Beat | -2.3% | -0.8% | 1.91× | +11.1% | Review |
| 2024Q4 | 2025-02-13 | BMO | 0.06 | +142.9% | Beat | -2.8% | +2.4% | 1.20× | -6.8% | Review |
| 2024Q3 | 2024-10-31 | BMO | -0.50 | -28.2% | Miss | -2.2% | -3.2% | 1.83× | -3.3% | Review |
| 2024Q2 | 2024-08-01 | BMO | 0.56 | +181.2% | Beat | +5.3% | +7.4% | 3.62× | -2.2% | Review |
| 2024Q1 | 2024-05-02 | BMO | -0.16 | +74.6% | Beat | +0.6% | -0.3% | 1.30× | +0.6% | Review |